Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Published version of a preprint
The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biological perspective but drug development is often hindered by toxicities and inadequate efficacy. Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks. Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clinical activities. Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacology while analyses in untransformed cells illuminates significant differences. To resolve this apparent disconnect, drug behaviors are described at the molecular level. Nonkinase binding studies and kinome interaction analysis (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacology, may contribute for abemaciclib, and confounds AG-024322 analysis. CDK2 and CDK6 cocrystal structures with the drugs identify the molecular interactions responsible for potency and kinase selectivity. Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome. Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket. Integrating clinical drug exposures into the analysis predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9). Understanding the molecular components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs. Mol Cancer Ther; 15(10); 2273–81. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinically, ribociclib has been shown to inhibit CDK4 preferentially and has also shown high drug concentrations at clinically relevant doses. 8”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [8]
In the citing paper
“abemaciclib was conceived to inhibit CDK4/CDK6 but has been shown to target other CDKs as well as CDK-unrelated kinases”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen et al., 2016
In the citing paper
“Palbociclib and ribociclib are selective for Cdk4, while abemaciclib inhibits both Cdk4 and Cdk230,31.”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [30]
In the citing paper
“Sequestration of cyclinB in such a manner may explain why abemaciclib blocks Cdk1 substrate phosphorylation and triggers a G2 arrest in cells31 despite lacking potent activity against Cdk1 in vitro30.”
From Allostery governs Cdk2 activation and differential recognition of CDK inhibitors (2021) · cites this paper as [30]
Citations
Cites
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767 · cited 3×
“Taken together, the clinical profiles of the third-generation drugs (7, 19, 28, 29) suggest that they impact patient biology in unique ways.”
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398 · cited 1×
“Synergy between CDK4/6 selective inhibitors and ER antagonists in blocking proliferation of ERþ breast cancer tumor cells is observed (21).”
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137 · cited 1×
“Previously, subsets of CDK drugs have been studied (41, 47–49) with more systematic comparisons occurring by literature reviews (4, 9, 19).”
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936 · cited 1×
“Previously, subsets of CDK drugs have been studied (41, 47–49) with more systematic comparisons occurring by literature reviews (4, 9, 19).”
Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors
Morrison, J. F. (1969) · Biochimica et Biophysica Acta (BBA) - Enzymology · doi:10.1016/0005-2744(69)90420-3 · Cited by 814 · cited 1×
“Ki values were derived from a fit to the Morrison equation (32, 33).”
Copeland, R. A. (2013) · Wiley eBooks · doi:10.1002/9781118540398 · Cited by 678 · cited 1×
“Active site titrations with ATP-competitive inhibitors revealed that the active sites were competent (31).”
Smart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., & Bricogne, G. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911056058 · Cited by 612
Research works printed but not linked: 2
- Vidula, 2016, Cyclin-dependent kinase 4/6 inhibitors for the treatment of breast cancer: a review of preclinical and clinical data, Clin Breast Cancer, 16, 8, 10.1016/j.clbc.2015.07.005 · DOI
- Copeland, 2005, Evaluation of enzyme inhibitors in drug discovery
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791
Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
Metadata
- Authors
- Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., Yu, X., Nagata, A., VanArsdale, T., & Murray, B. W.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Murray, Brion W.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-10-01
- Volume
- 15
- Issue
- 10
- Pages
- 2273-2281
- ISSN
- 1535-7163 (ISSN-L)
- 1538-8514
- OpenAlex
- W2491062142
- Cited by
- 444
- References
- 53
- Citations by year
- 2026: 35 · 2025: 59 · 2024: 59 · 2023: 58 · 2022: 48 · 2021: 52 · 2020: 42 · 2019: 39 · 2018: 27 · 2017: 25
- FWCI
- 27.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Cancer Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- cyclin-dependent kinase inhibitors, CDK4/6 inhibitors, drug selectivity, kinase specificity, dinaciclib, palbociclib, ribociclib, abemaciclib, CDK2, CDK6, ATP binding site, kinase redundancy, anticancer drug development
- MeSH terms
- Animals, Antineoplastic Agents, Cell Survival, Drug Interactions, Epithelial Cells, Humans, Leukocytes, Mononuclear, Models, Molecular, Molecular Conformation, Phosphorylation, Protein Binding, Cluster Analysis, Cyclin-Dependent Kinases, Drug Resistance, Neoplasm, Myocytes, Cardiac, Cell Line, Tumor, Protein Kinase Inhibitors, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0300
- The paper
- Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., Yu, X., Nagata, A., VanArsdale, T., & Murray, B. W. (2016). Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0300
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.